284 related articles for article (PubMed ID: 31721316)
41. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
Alexis AF; Rendon M; Silverberg JI; Pariser DM; Lockshin B; Griffiths CE; Weisman J; Wollenberg A; Chen Z; Davis JD; Li M; Eckert L; Gadkari A; Shumel B; Rossi AB; Graham NM; Ardeleanu M
J Drugs Dermatol; 2019 Aug; 18(8):804-813. PubMed ID: 31424712
[TBL] [Abstract][Full Text] [Related]
42. Perception of the coronavirus pandemic by patients with atopic dermatitis - Results from the TREATgermany registry.
Helmert C; Siegels D; Haufe E; Abraham S; Heratizadeh A; Kleinheinz A; Harder I; Schäkel K; Effendy I; Wollenberg A; Sticherling M; Stahl M; Worm M; Schwichtenberg U; Schwarz B; Rossbacher J; Buck PM; Schenck F; Werfel T; Weidinger S; Schmitt J;
J Dtsch Dermatol Ges; 2022 Jan; 20(1):45-57. PubMed ID: 34958179
[TBL] [Abstract][Full Text] [Related]
43. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective.
Chia SY; Wee LWY; Koh MJA
Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751
[TBL] [Abstract][Full Text] [Related]
44. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Sirna R; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavò SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Savi E; Stingeni L; Romano A; Argenziano G;
J Dermatolog Treat; 2021 Aug; 32(5):507-513. PubMed ID: 31647347
[TBL] [Abstract][Full Text] [Related]
45. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort.
Silverberg JI; Simpson B; Abuabara K; Guttman-Yassky E; Calimlim B; Wegzyn C; Krueger W; Gamelli A; Munoz B; Faller RW; Crawford JM; Grada A; Eichenfield LF;
J Am Acad Dermatol; 2023 Sep; 89(3):519-528. PubMed ID: 37150299
[TBL] [Abstract][Full Text] [Related]
46. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world.
Jang DH; Heo SJ; Kook HD; Lee DH; Jung HJ; Park MY; Ahn J
Sci Rep; 2021 Dec; 11(1):23539. PubMed ID: 34876623
[TBL] [Abstract][Full Text] [Related]
47. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden.
Katoh N; Saeki H; Kataoka Y; Etoh T; Teramukai S; Takagi H; Tajima Y; Ardeleanu M; Rizova E; Arima K;
J Dermatol; 2019 Apr; 46(4):290-300. PubMed ID: 30756423
[TBL] [Abstract][Full Text] [Related]
48. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.
Bosma AL; Ouwerkerk W; Heidema MJ; Prieto-Merino D; Ardern-Jones MR; Beattie P; Brown SJ; Ingram JR; Irvine AD; Ogg G; Patel P; Reynolds NJ; Hearn RMR; Wan M; Warren RB; Woolf RT; Hyseni AM; Gerbens LAA; Spuls PI; Flohr C; Middelkamp-Hup MA;
JAAD Int; 2023 Mar; 10():14-24. PubMed ID: 36387062
[TBL] [Abstract][Full Text] [Related]
49. High recurrence rate of eczema herpeticum in moderate/severe atopic dermatitis -TREATgermany registry analysis.
Traidl S; Heinrich L; Siegels D; Rösner L; Haufe E; Harder I; Abraham S; Ertner K; Kleinheinz A; Schäkel K; Wollenberg A; Effendy I; Quist S; Asmussen A; Wildberger J; Weisshaar E; Wiemers F; Brücher JJ; Weidinger S; Schmitt J; Werfel T;
J Dtsch Dermatol Ges; 2023 Dec; 21(12):1490-1498. PubMed ID: 37814394
[TBL] [Abstract][Full Text] [Related]
50. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
[TBL] [Abstract][Full Text] [Related]
51. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): Baseline treatment patterns and unmet needs assessment.
Wei W; Ghorayeb E; Andria M; Walker V; Schnitzer J; Kennedy M; Chen Z; Belland A; White J; Silverberg JI
Ann Allergy Asthma Immunol; 2019 Oct; 123(4):381-388.e2. PubMed ID: 31325566
[TBL] [Abstract][Full Text] [Related]
52. Analysis of correlations between patient-oriented SCORAD (PO-SCORAD) and other assessment scores of atopic dermatitis severity and quality of life.
Coutanceau C; Stalder JF
Dermatology; 2014; 229(3):248-55. PubMed ID: 25196258
[TBL] [Abstract][Full Text] [Related]
53. Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults.
Barrett A; Hahn-Pedersen J; Kragh N; Evans E; Gnanasakthy A
Patient; 2019 Oct; 12(5):445-459. PubMed ID: 31270775
[TBL] [Abstract][Full Text] [Related]
54. Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study.
Calzavara-Pinton P; Čelakovská J; Lapeere H; Holzer G; Al-Ahmad M; Chu CY; Ferrucci SM; Kataoka Y; Rossi M; Fomina DS; Chung WH; Tzellos T; Fougerousse AC; Wu J; Ardeleanu M; Ozturk ZE
Adv Ther; 2023 Dec; 40(12):5366-5382. PubMed ID: 37801232
[TBL] [Abstract][Full Text] [Related]
55. Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials.
Penton H; Jayade S; Selveindran S; Heisen M; Piketty C; Ulianov L; Jabbar-Lopez ZK; Silverberg JI; Puelles J
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2549-2571. PubMed ID: 37747670
[TBL] [Abstract][Full Text] [Related]
56. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
57. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial.
Tsianakas A; Luger TA; Radin A
Br J Dermatol; 2018 Feb; 178(2):406-414. PubMed ID: 28845523
[TBL] [Abstract][Full Text] [Related]
58. Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study.
Oosterhaven JAF; Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
J Dermatol; 2019 Aug; 46(8):680-685. PubMed ID: 31187925
[TBL] [Abstract][Full Text] [Related]
59. Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience.
Ferrucci S; Casazza G; Angileri L; Tavecchio S; Germiniasi F; Berti E; Marzano AV; Genovese G
J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32183179
[TBL] [Abstract][Full Text] [Related]
60. Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
Eyerich K; Gooderham MJ; Silvestre JF; Shumack SP; Mendes-Bastos P; Aoki V; Ortoncelli M; Silverberg JI; Teixeira HD; Chen SH; Calimlim BM; Takemoto S; Sancho C; Fritz B; Irvine AD
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):340-353. PubMed ID: 37669868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
